TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01993225
Drug: Placebo Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01993225
Drug: AndroGel 1.62%
Normalized name: Androgel 1.62% Transdermal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01993225
Drug: Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02265302
Drug: BIIL 284 oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02265302
Drug: BIIL 284 wetability improved formulation (WIF) tablets
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02265302
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02203474
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05506787
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02795273
Drug: Grass-SPIRE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02795273
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03978234
Drug: AbobotulinumtoxinA 300 UNT
Normalized name: abobotulinumtoxinA 300 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: AbobotulinumtoxinA 300 UNT
Study: NCT01970462
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients are reandomized to Sitagliptin or placebo for 6 weeks post-operatively
Study: NCT01639456
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Infused intravenously 60 mg/kg x day -5
Study: NCT02144064
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group A (n = 100) are put on Inj. UFH (Cal-heparin) 5000 U subcutaneous twice daily plusAspirin 81 mg/day (Juspirin) with the ﬁrst positive pregnancy test, Inj. UFH is given either into anterior abdominal wall or anterior aspect of thigh subcutaneously
Study: NCT03311412
Drug: Sym021
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.
Study: NCT03311412
Drug: Sym023
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sym023 is a recombinant, fully human antibody that binds TIM-3 and induces activation of immune cells.
Study: NCT03728504
Drug: ASN002
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of ASN002 for 32 weeks
Study: NCT03728504
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dose of Placebo Oral Tablet for 16 weeks
Study: NCT04209530
Drug: EN3835
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagenase Clostridium Histolyticum (CCH)
Study: NCT00894231
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar tablet
Study: NCT02633137
Drug: R-CHOP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Rituximab 375 mg/m\^2 IVPB with premedications Day 1~* Cyclophosphamide 750 mg/m\^2 IVPB Day 1~* Doxorubicin 50 mg/m\^2 IVP Day 1~* Vincristine 1.4 mg/m\^2 IVP (capped at 2 mg) Day 1~* Prednisone 100 mg PO Daily on Days 1-5 or 2-6
Study: NCT04495179
Drug: AZD4635
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive AZD4635 orally daily
Study: NCT03731689
Drug: Intrauterine lavage therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrauterine lavage treatment was performed within 3 to 7 days after the first menstrual period after surgery.
Study: NCT00449176
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo twice daily for 15 weeks
Study: NCT00594867
Drug: Acetaminophen - 4 grams per day + Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen - 4 grams per day + Placebo
Study: NCT00594867
Drug: Acetaminophen 4 gram per day + Aspirin 325 mg per day
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 4 gram per day + Aspirin 325 mg per day
Study: NCT02217930
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02540824
Drug: Apatinib single agent arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: For RET-fusion positive advanced NSCLC patients who failed to previous treatment,treat with apatinib, single agent, 750mg once daily, p.o until disease progression
Study: NCT00244296
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01749982
Drug: Choline bitartrate
Normalized name: Choline Bitartrate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01749982
Drug: Choline bitartrate + Betaine
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03392714
Drug: R-B(O)AD
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: rituximab 375 mg/m2 on day 1; vincristine 1.4 mg/m2 on day 1, omitted in patients ≥70 years of age due to risk of neurotoxicity; bendamustine 75 mg/m2 over 1 h on days 2 and 3; cytarabine 1000 mg/m2 over 3 h on days 2-4; dexamethasone 20 mg on days 1-4, administered intravenously
Study: NCT03579030
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule matched to an RTA 1701 capsule
Study: NCT02685657
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02685657
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02679261
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration placebo
Study: NCT01239030
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT00434382
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00434382
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00434382
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00859079
Drug: Human regular insulin intravenously
Normalized name: insulin, regular, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human regular insulin intravenously according to the Munich-registry.
Study: NCT00683644
Drug: Zinc
Normalized name: Zinc
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc taken once daily
Study: NCT00683644
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules taken once daily
Study: NCT00141154
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00141154
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00410033
Drug: soluble human insulin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00410033
Drug: isophane human insulin
Normalized name: insulin isophane, human
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03215797
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine 5ug/ml IV infusion at a rate of 5 ml/h in case of hypotension
Study: NCT00114010
Drug: AMA1/Alhydrogel
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04653766
Drug: Ir-CPI - Dose 2
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 participants received a single intravenous dose of 3.0 mg/kg of Ir-CPI during 6 hours
Study: NCT04653766
Drug: Ir-CPI - Dose 4
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 participants received a single intravenous dose of 9.0 mg/kg of Ir-CPI during 6 hours
Study: NCT04653766
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For each dose group, 2 additional participants received a single intravenous dose of placebo during 6 hours (8 in total).
Study: NCT00575926
Drug: LingZhi capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: LingZhi or Placebo 300 mg x 4 or 300 mg x 6 capsules daily according to age group
Study: NCT03088826
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg Acetaminophen
Study: NCT01527734
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1ml once or twice a day for 1 or 2 days.
Study: NCT03973008
Drug: Adjuvant Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxalis 130mg/m2 intravenous drip on day 1, tegio 80-120 mg daily, twice, half an hour after breakfast and dinner, for 14 consecutive days
Study: NCT03230708
Drug: convention drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: according to usage method of drugs
Study: NCT00093834
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: This trial will be a dose ranging study of a fixed sequence of drug doses in a three by three factorial matrix modeled after the theories of Plackett and Burman (Plackett et al., 1946), and is designed to determine the doses of CY and DOX that maximize the immunologic response to vaccination
Study: NCT00093834
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This trial will be a dose ranging study of a fixed sequence of drug doses in a three by three factorial matrix modeled after the theories of Plackett and Burman (Plackett et al., 1946), and is designed to determine the doses of CY and DOX that maximize the immunologic response to vaccination
Study: NCT00313820
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.
Study: NCT00265889
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg IV over 2 hours x 2 days
Study: NCT00860379
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV saline as placebo
Study: NCT03519854
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl administered as a fast IV bolus dose (within 30 seconds).
Study: NCT03519854
Drug: Esmeron®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmeron® administered at 0.6 mg/kg as a fast IV bolus (within 10 seconds), dosed according to participant actual body weight.
Study: NCT01515748
Drug: S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + 5-chloro-2, 4-dihydroxypyridine (CDHP) (Gimeracil) + Oxo (Oteracil)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study: NCT01458197
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, qd, 12 weeks
Study: NCT00506064
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.15 mg/kg by mouth (PO) Daily
Study: NCT01821261
Drug: Mouth Rinse 500347078842
Normalized name: phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 ml of mouth rinse 500347078842 for 60 seconds, twice daily
Study: NCT01821261
Drug: Toothpaste 035000513007
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately one inch of toothpaste 035000513007, twice daily
Study: NCT02535104
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle control
Study: NCT02285439
Drug: MEK162
Approvals — FDA: no, EMA: no, PMDA: no
Description: • MEK162 is currently supplied as film-coated tablets in dose strength of 15 mg. The film-coated tablets consist of MEK162 drug substance, lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, and a commercial film coating. The original tablets are yellow to dark yellow capsule-shaped
Study: NCT00541450
Drug: Matching Placebo to Sita/Met FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo to Sita/Met FDC - 50/500 mg b.i.d. for 4 weeks and then 50/1000 mg b.i.d. orally for a 28-wk treatment period (Week 12 to Week 40).
Study: NCT00290589
Drug: Intramuscular methylprednisolone acetate
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular methylprednisolone acetate 160mg
Study: NCT04648540
Drug: Fentanyl 1 mic/kg/hr
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Group II (OA) patients will receive a continuous infusion of Fentanyl (1 mic/kg/h) Morphine 0.1 mg/kg PRN will be administered every 8 hours for postoperative analgesia
Study: NCT00137566
Drug: acetaminophen (paracetamol)
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol tablets, 50 mg/kg/day for 3 days.
Study: NCT02291679
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01535768
Drug: Aqueous Suppressant Eye Drops
Normalized name: Buckley's Cough Suppressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous suppressant eye drops added stepwise to achieve IOP between 7-10mmHg. First, a beta blocker eye drop (timolol 0.25% 1 gtts in study eye BID OR timolol 0.5% 1 gtts in study eye BID).~Next, a topical carbonic anhydrase inhibitor eye drop. (brinzolamide 1% 1 gtts in study eye TID OR dorzolamide 2% 1 gtts in study eye TID) Next, a topical alpha agonist eye drop. (brimonidine 0.1% 1 gtts in study eye TID OR brimonidine 0.15% 1 gtts in study eye TID).~Next, a topical prostaglandin analogue eye drop. (latanoprost 0.005% 1 gtts in study eye qhs OR travoprost 0.004% 1 gtts in study eye qhs OR bimatoprost 0.01% 1 gtts in study eye qhs OR bimatoprost 0.03% 1 gtts in study eye qhs) Finally, stop the topical carbonic anhydrase inhibitor eye drop and start oral acetazolamide. (acetazolamide 250mg PO OD)
Study: NCT00456833
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03583749
Drug: Subcutaneous (SC) route for antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving one of the three antibiotics by SC route without any randomization because the route will be chosen before inclusion by the physician in charge.
Study: NCT03583749
Drug: Intravenous (IV) route for antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving one of the three antibiotics by IV route without any randomization because the route will be chosen before inclusion by the physician in charge.
Study: NCT03153579
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing mannitol looking identical to LSD
Study: NCT01068158
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: up to 4 ounces of topical vehicle control to head and scalp on day 1.
Study: NCT03620253
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to the placebo group will receive 100 mg placebo capsules for 1 week, followed by 200 mg for 7 weeks, which they will take daily in the morning. During this time, participants will complete questionnaires and neurocognitive tests, and report adverse events at study visits.
Study: NCT02452268
Drug: NIZ985
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of hetIL-15 three times a week for two consecutive weeks
Study: NCT02452268
Drug: PDR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: • PDR001 is a human monoclonal antibody (MAb) administered day 1 of each cycle
Study: NCT02276222
Drug: Spiriva® 18 mcg QD Handihaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
Study: NCT02617017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules of placebo will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
Study: NCT01951625
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00642187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00326131
Drug: Oral Taxane
Normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02598505
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00785408
Drug: AC2307
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous, twice daily, low dose
Study: NCT00785408
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous, twice daily, low dose
Study: NCT00785408
Drug: AC2307
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous, twice daily, middle dose
Study: NCT00785408
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous, twice daily, middle dose
Study: NCT00785408
Drug: AC2307
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous, twice daily, high dose
Study: NCT00785408
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous, twice daily, high dose
Study: NCT03673696
Drug: HEC74647PA Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule administered orally once daily
Study: NCT02706119
Drug: Regular insulin added to TPN bag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular insulin is human insulin produced in Saccharomyces cerevisiae by recombinant DNA technology.
Study: NCT01170221
Drug: TR-701 FA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral TR-701 FA 200 mg once daily for six days followed by four days of placebo.
Study: NCT03329287
Drug: SSRIs and/or SNRIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs and/or SNRIs at a recommended dosage.
Study: NCT01047592
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo,oral, for 12 weeks
Study: NCT00054236
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide IV over 2 hours on days -3 to -2
Study: NCT00559650
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Will be standard therapy and placebo versus, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours
Study: NCT00004014
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin HCl liposome IV over 45 minutes every 3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then every 9 weeks thereafter.
Study: NCT00086736
Drug: oral eflornithine placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00833560
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In Part 1, cyclophosphamide with dose ranging from 900 to 1500 mg will be administered intravenously on Day 1 of each 21 day cycle for 3 cycles to determine optimal dose. In Part 2, optimal dose determined in Part 1 will be administered on Day 1 of each 21 day cycle for 3 cycles.
Study: NCT00999466
Drug: AZD8848
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray, solution 0.6mg/ mL. Once weekly for 7 weeks, 8 doses in total.
Study: NCT00999466
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray, solution. Once weekly for 7 weeks, 8 doses in total.
Study: NCT00649168
Drug: Parlodel® (bromocriptine mesylate) capsules, USP 5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
Study: NCT00477230
Drug: Standard Anti-arrhythmic Drug (AAD) Therapy
Normalized name: INVESTIGATIONAL ANTI-NEOPLASTIC DRUGS, GENE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication as prescribed by physician.
Study: NCT00225056
Drug: docetaxel and capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01229241
Drug: local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: postoperative 48h epidural continuous infusion,~1. ropivacaine 0,2% (250ml)+ sufentanil 0,75mcg/ml~2. levobupivacaine 0,125% (250ml)+ sufentanil 0,75mcg/ml
Study: NCT01791725
Drug: ELND005
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01791725
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00738946
Drug: Intermittent preventive treatment with AQ+ SP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amodiaquine (10 mg/kg over 3 days) and Sulfadoxine Pyrimethamine (25 mg of sulfadoxine + 1.25 mg of pyrimethamine per kg in a single dose) or placebo administered over 3 rounds of one month interval
Study: NCT00332319
Drug: GW679769
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00776321
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03574415
Drug: DWP14012
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 tablets
Study: NCT03574415
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWP14012 placebo-matching tablets
Study: NCT00992602
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00002481
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003203
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03530930
Drug: Comarum Palustre
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comarum Palustre tablets 500 mg BID, 1 month
Study: NCT01313702
Drug: polipillV1
Approvals — FDA: no, EMA: no, PMDA: no
Description: polipill version 1: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg
Study: NCT01313702
Drug: polipillV2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polipill version 2: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg.
Study: NCT01313702
Drug: usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: the drugs used in clinical practice, defined by physician